Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H36F2O5 |
| Molecular Weight | 478.5685 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C
InChI
InChIKey=HHJIUUAMYGBVSD-YTFFSALGSA-N
InChI=1S/C27H36F2O5/c1-5-6-7-23(33)34-14-21(31)24-15(2)10-17-18-12-20(28)19-11-16(30)8-9-26(19,4)27(18,29)22(32)13-25(17,24)3/h8-9,11,15,17-18,20,22,24,32H,5-7,10,12-14H2,1-4H3/t15-,17+,18+,20+,22+,24-,25+,26+,27+/m1/s1
| Molecular Formula | C27H36F2O5 |
| Molecular Weight | 478.5685 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdfCurator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332
Sources: https://web.archive.org/web/20170630002752/http://ca.gsk.com/media/1187415/nerisone.pdf
Curator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332
Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P04083 Gene ID: 301.0 Gene Symbol: ANXA1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NERISONE Approved UseNERISONE® (diflucortolone valerate) preparations are indicated for the topical treatment of corticosteroid-responsive acute and chronic skin diseases, where anti-inflammatory, anti-allergic and anti-pruritic action is required for a maximum duration of 4 weeks. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cutaneous polyarteritis nodosa successfully treated with topical diflucortolone valerate: a case report & review of the literature. | 2014 |
|
| Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations. | 2013 |
|
| Congenital infantile digital fibromatosis: a case report and review of the literature. | 2009-12-28 |
|
| Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. | 1998-12 |
|
| A test of the half-side comparative design in the clinical evaluation of topical steroids, using diflucortolone and betamethasone creams. | 1985-10 |
|
| [Clinical trial of diflucortolone. Preliminary report]. | 1981 |
|
| [Clinical comparative study of between difluocortolone and flumethasone]. | 1977 |
|
| [Use of diflucortolone in various dermatological processes]. | 1976-10 |
Patents
Sample Use Guides
Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:39:38 GMT 2025
by
admin
on
Mon Mar 31 19:39:38 GMT 2025
|
| Record UNII |
1A63Z067C8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01694MIG
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
DTXSID1048598
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
1A63Z067C8
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
DBSALT001149
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
23035
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | RxNorm | ||
|
Diflucortolone valerate
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
CHEMBL509924
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
m4432
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
261-655-8
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
100000092797
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
59198-70-8
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
C013486
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY | |||
|
91670
Created by
admin on Mon Mar 31 19:39:38 GMT 2025 , Edited by admin on Mon Mar 31 19:39:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |